Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia 2019 (ICALL) /
B-lymphoid transcriptional programme as a barrier against malignant transformation in acute lymphoblastic leukaemia

17th - 19th May 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 672
Rating:

Prof Markus Müschen - City of Hope Comprehensive Cancer Center, Los Angeles, USA

Prof Markus Müschen talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about how inhibitory phosphatases regulate the survival of B-lymphocytes.

He explains how phosphatases are necessary for oncogene signalling and the inhibition of these may prevent relapse and overcome drug resistance in acute lymphoblastic leukaemia (ALL).

Prof Müschen mentions the possibility of incorporating precision medicine in this approach, along with the differences between various subtypes of leukaemia.

He concludes by summarising the specific therapeutic targets in this signalling pathway.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation